Anxiolytics: Past, present, and future agents

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 3, 2003, Pages 3-6

  Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ALPRAZOLAM; AMFEBUTAMONE; AMINOGLUTETHIMIDE; ANTACID AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMIDE; BUSPIRONE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIAZEPAM; FLUOXETINE; FLUVOXAMINE MALEATE; GLUTETHIMIDE; IMIPRAMINE; LORAZEPAM; MEPROBAMATE; METHAQUALONE; METHYPRYLON; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OXAZEPAM; PARALDEHYDE; PAROXETINE; PHENELZINE; PHENOBARBITAL; RECEPTOR SUBTYPE; SERTRALINE; TIAGABINE; TRANMEP; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; TYRAMINE; VENLAFAXINE;

ANXIETY DISORDER; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; FORECASTING; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HISTORY, 20TH CENTURY; HUMANS; RECEPTORS, GABA; SYNAPTIC TRANSMISSION;

EID: 0037237617     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Gulley LR, Nemeroff CB. The neurobiological basis of mixed depressionanxiety states. J Clin Psychiatry 1993: 54(1, suppl): 16-19
2. Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research. Acta Psychiatr Scand Suppl 2000;406:7-13
3. Löw K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:131-134
4. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999; 401:796-800
5. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962;119:4324-4338
6. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study, Acta Psychiatr Scand 1993;88: 1-11
7. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry 1987;48(12, suppl): 12-16
8. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-535
9. Delle CR, Pancheri P, Casacchia M, et al. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 1995;15:12-19
10. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996;57:287-291
11. Gammans RE, Stringfellow JC, Hvizdos AJ, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992;25:193-201
12. Figgitt DP, McClellan KJ. Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs 2000;60:925-954
13. Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclic anti-depressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;403:39-49
14. Ninan PT. Use of venlafaxine in other psychiatric disorders. Depress Anxiety 2000;12(suppl 1):90-94
15. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-37
16. Haddad PM. Antidepressant discontinuation syndrome. Drug Saf 2001;24: 183-197
17. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha 1 subtype. Nat Neurosci 2000;3:587-592
18. Gruener D. Tiagabine as an augmenting agent for the treatment of anxiety. Presented at the 22nd National Conference of the Anxiety Disorders Association of America; March 21-24, 2002; Austin, Tex